logo
  

CureVac: CV2CoV Shows Comparable Antibody Levels To Licensed MRNA Vaccine In Preclinical Study

CureVac N.V. (CVAC) published the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GSK. The data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Comirnaty. Neutralizing antibody levels measured following full vaccination of animals with either 12µg of CV2CoV or a 30µg standard dose of Comirnaty were shown to be highly comparable, as per the study.

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected than animals vaccinated with CVnCoV in the study.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement company Lowe's and pet retailer Petco Health and Wellness Co. are set to launch a pilot store-in-store program whereby a total home solution will be offered to customers by bringing home improvement as well as pet care products, services and expertise together under the same roof. Chevron Corporation (CVX) reported fourth quarter profit of $5.1 billion or $2.63 per share, compared to a loss of $665 million or $0.33 per share, previous year. The company's U.S. upstream operations earned $2.97 billion, compared to $101 million, a year ago. The company said the improvement was primarily... While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) initiated its earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now expects earnings per share to grow in double-digit percentage and adjusted earnings per share growth...
RELATED NEWS
Follow RTT